Drag a card by its title · ⚙ to size, swap or remove

The company

Zevra Therapeutics, Inc.

ZVRA · Nasdaq

Health CareBiotechnologyJust dropped out

ZVRA stood above a rising 150-day average in 24 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 11.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Just dropped out
Weeks in an uptrend: out for 1
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $4.8M
Officials’ trades on record: 0
Institutions holding: 153 (+10)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 24 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months13

Buyers · sellers0 · 6

Who	Did	Shares	Traded
Neil F. McFarlanePresident and CEO	sold	20,000at $11.25	12 Oct 2026filed 13 Oct 2026
Rahsaan ThompsonChief Legal & Compliance	sold	42,666at $11.13	14 Aug 2026filed 17 Aug 2026
Corey Michael WattonDirector	sold	12,300at $11.25	10 Aug 2026filed 12 Aug 2026
Rahsaan ThompsonChief Legal & Compliance	sold	34,557at $12.68	22 Jun 2026filed 23 Jun 2026
Rahsaan ThompsonChief Legal & Compliance	sold	1,794at $11.30	11 May 2026filed 13 May 2026
Neil F. McFarlanePresident and CEO	sold	14,625at $8.56	9 Feb 2026filed 10 Feb 2026
Timothy J. SangiovanniSVP, Finance & Corp Controller	sold	3,000at $9.18	3 Feb 2026filed 4 Feb 2026
Joshua SchaferCCO	sold	10,500at $9.19	3 Feb 2026filed 4 Feb 2026
Neil F. McFarlanePresident and CEO	sold	91,000at $9.38	2 Feb 2026filed 2 Feb 2026
Timothy J. SangiovanniSVP, Finance & Corp Controller	sold	1,750at $8.82	30 Jan 2026filed 2 Feb 2026
Rahsaan ThompsonChief Legal & Compliance	sold	4,080at $8.83	30 Jan 2026filed 2 Feb 2026
Adrian W. QuartelChief Medical Officer	sold	4,533at $8.83	30 Jan 2026filed 2 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders153+10 on the quarter

New · exited30 · 19

Reported value$639.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
BlackRock, Inc.added · filed 7 Aug 2026	5,108,871$73.3M	+652,395+14.6%
FMR LLCadded · filed 13 Aug 2026	4,915,717$70.5M	+1,703,840+53.0%
Woodline Partners LPadded · filed 14 Aug 2026	4,785,771$68.6M	+1,334,828+38.7%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	2,638,910$37.8M	+169,582+6.9%
Nantahala Capital Management, LLCreduced · filed 14 Aug 2026	1,797,476$25.8M	-724,460−28.7%
STATE STREET CORPadded · filed 7 Aug 2026	1,681,999$24.1M	+120,430+7.7%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	1,540,936$22.1M	+169,079+12.3%
D. E. Shaw & Co., Inc.added · filed 14 Aug 2026	1,306,949$18.7M	+460,492+54.4%
Qube Research & Technologies Ltdadded · filed 14 Aug 2026	1,241,343$17.8M	+399,024+47.4%
MORGAN STANLEYadded · filed 13 Aug 2026	1,203,875$17.3M	+11,613+1.0%